Patients’ characteristics at diagnosis
| Characteristic . | Disease Subtype . | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| CM/MIS (n = 8) . | ISM* (n = 27) . | Advanced SM (n = 13) . | |||||||
| No. . | % . | Median (range) . | No. . | % . | Median (range) . | No. . | % . | Median (range) . | |
| Age, years | 36 (25-58) | 52 (22-81) | 66 (43-78) | ||||||
| Sex | |||||||||
| Male | 5 | 63 | 15 | 56 | 5 | 38 | |||
| Female | 3 | 37 | 12 | 44 | 8 | 62 | |||
| Serum CCL2 level, pg/mL | 318.8 (115.1-595.4) | 289 (159.5-865) | 513.9 (238-2367) | ||||||
| Mast cell infiltration (% BM histology) | NA | 10 (2-50) | 32 (5-90) | ||||||
| KIT D816V mutation (% positive) | 3/5 | 60 | 21/22 | 95 | 9/12 | 75 | |||
| KIT D816V mutant allele burden | 0.10 (0.04-0.16) | 0.63 (0.03-9.90) | 14.08 (0.01-50.18) | ||||||
| Serum tryptase level, µg/L | 10.5 (4.4-55.1) | 59.5 (11-885) | 93.8 (1.8-1432) | ||||||
| BM microvessel density (No./0.25 mm2) | NA | 36 (13-87) | 37 (9-110) | ||||||
| Patients with BM fibrosis | |||||||||
| Grade 0 | NA | 2/25 | 8 | 2/13 | 15 | ||||
| Grade 1 | NA | 19/25 | 76 | 6/13 | 47 | ||||
| Grade 2 | NA | 3/25 | 12 | 3/13 | 23 | ||||
| Grade 3 | NA | 1/25 | 4 | 2/13 | 15 | ||||
| Deaths | |||||||||
| Patients who died during observation | 0/8 | 0 | 5/27 | 19 | 7/13 | 54 | |||
| Related to disease progression | 1/3† | 33 | 5/7 | 71 | |||||
| Unrelated to disease progression | 2/3† | 67 | 2/7 | 29 | |||||
| Characteristic . | Disease Subtype . | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| CM/MIS (n = 8) . | ISM* (n = 27) . | Advanced SM (n = 13) . | |||||||
| No. . | % . | Median (range) . | No. . | % . | Median (range) . | No. . | % . | Median (range) . | |
| Age, years | 36 (25-58) | 52 (22-81) | 66 (43-78) | ||||||
| Sex | |||||||||
| Male | 5 | 63 | 15 | 56 | 5 | 38 | |||
| Female | 3 | 37 | 12 | 44 | 8 | 62 | |||
| Serum CCL2 level, pg/mL | 318.8 (115.1-595.4) | 289 (159.5-865) | 513.9 (238-2367) | ||||||
| Mast cell infiltration (% BM histology) | NA | 10 (2-50) | 32 (5-90) | ||||||
| KIT D816V mutation (% positive) | 3/5 | 60 | 21/22 | 95 | 9/12 | 75 | |||
| KIT D816V mutant allele burden | 0.10 (0.04-0.16) | 0.63 (0.03-9.90) | 14.08 (0.01-50.18) | ||||||
| Serum tryptase level, µg/L | 10.5 (4.4-55.1) | 59.5 (11-885) | 93.8 (1.8-1432) | ||||||
| BM microvessel density (No./0.25 mm2) | NA | 36 (13-87) | 37 (9-110) | ||||||
| Patients with BM fibrosis | |||||||||
| Grade 0 | NA | 2/25 | 8 | 2/13 | 15 | ||||
| Grade 1 | NA | 19/25 | 76 | 6/13 | 47 | ||||
| Grade 2 | NA | 3/25 | 12 | 3/13 | 23 | ||||
| Grade 3 | NA | 1/25 | 4 | 2/13 | 15 | ||||
| Deaths | |||||||||
| Patients who died during observation | 0/8 | 0 | 5/27 | 19 | 7/13 | 54 | |||
| Related to disease progression | 1/3† | 33 | 5/7 | 71 | |||||
| Unrelated to disease progression | 2/3† | 67 | 2/7 | 29 | |||||